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Abstract
Frequent mutations of p53 in human cancers exemplify its crucial role as a tumor suppressor transcription factor,
and p21, a transcriptional target of p53, plays a central role in surveillance of cell-cycle checkpoints. Our previous
study has shown that FATS stabilize p21 to preserve genome integrity. In this study we identified a novel transcript
variant of FATS (GenBank: GQ499374) through screening a cDNA library from mouse testis, which uncovered the
promoter region of mouse FATS. Mouse FATS was highly expressed in testis. The p53-responsive elements existed
in proximal region of both mouse and human FATS promoters. Functional study indicated that the transcription of
FATS gene was activated by p53, whereas such effect was abolished by site-directed mutagenesis in the p53-RE of
FATS promoter. Furthermore, the expression of FATS increased upon DNA damage in a p53-dependent manner.
FATS expression was silent or downregulated in human cancers, and overexpression of FATS suppressed tumori-
genicity in vivo independently of p53. Our results reveal FATS as a p53-regulated gene to monitor genomic
stability.
Findings
Malfunction of the p53 pathway is an almost universal
hallmark of human tumors, and mutations selected for
t u m o r i g e n e s i sa r eu s u a l l ys i n g l eb a s es u b s t i t u t i o n st h a t
result in amino acid substitutions in the DNA-binding
domain of p53 [1,2]. As a transcription factor, p53 con-
trols multiple cellular functions by inducing or repressing
target genes with p53 response elements (REs). Among
main outcomes after the activation of p53, cell-cycle
arrest permits repair processes to act and plays a key role
in surveillance of genome stability, which is executed pre-
dominately by a downstream target gene p21 [3,4].
Fragile-site associated tumor suppressor (FATS) is a
newly identified candidate tumor suppressor whose gene
locus is frequently deleted in spontaneous tumors. Strik-
ingly, the deletion frequency of FATS gene in tumors
increases further after treatment of low dose ionizing
radiation (IR), which is tightly linked to DNA-damage-
induced tumorigenesis and loss of FATS-mediated inhi-
bition of p21 turnover [5]. However, it’su n k n o w n
whether crosstalk occurs between p53-p21 pathway and
FATS-p21 pathway.
To understand better the functional network of FATS,
we investigated the transcriptional regulation of FATS.
In this study, we identified a novel FATS transcript var-
iant with a distinct 5′ untranslated region (UTR). The
mRNA level of mouse FATS was highest in testis.
Furthermore, we found that the transcription of FATS
was activated by p53, and that FATS possessed antican-
cer activity independently of p53.
The NH2-terminal region of FATS, encoded by the
largest coding exon that is susceptible to DNA damage
and frequently deleted in tumors, plays a critical role in
FATS-mediated regulation of p21 [5]. In an effort to
identify the full-length mRNA of FATS, we took advan-
tage of a mouse testis plasmid cDNA library based on
the sequence of the first coding exon and cloning vec-
tor. Rapid amplification of cDNA Ends (RACE) was
then applied to obtain the full-length sequence of FATS
mRNA. The results of library screening revealed a pre-
viously unknown transcript variant that possessed a
novel 5′ untranslated region (UTR), which was spliced
from two exons (Figure 1A and 1B). This transcript var-
iant of FATS (GenBank accession number: GQ499374)
shared all the coding exons with a previously existing
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any medium, provided the original work is properly cited.Figure 1 Identification of a FATS transcription variant with high expression in mouse testis.( A )T h es e q u e n c eo f5 ’-UTR in FATS mRNA (GenBank
accession number: GQ499374) through screening a mouse testis plasmid cDNA library (Stratagene #975304). In brief, the non-coding sequence ahead of
the first coding exon of FATS gene was amplified by PCR using the primers specific to pMyr XR vector (Stratagene) and FATS coding region,
respectively, and subjected to DNA sequencing subsequently. Primer sequences were as follows: pMyr-fw, 5’-ATGGGGAGTAGCAAGAGCAA-3’; FATS-rv,
5’-TCTTTTCATCAATCAGCCGG-3’. Similar approach was applied to verify the mRNA sequence downstream of the first coding exon. Primer sequences
were as follows: FATS-fw, 5’-CATATTCCCGGCTGGAGTTA-3’; pMyr-rv, 5’-CTTTTCGGTTAGAGCGGATG-3’. The sequence of exon 2 is shaded, and the start
codon ATG is in bold letters. (B) The genomic organization of FATS gene. FATS transcript GQ499374 differed from a previously submitted transcription
variant (GenBank accession number: NM_001081331) only in 5’ UTR. The coding regions of exons were shaded. (C) The p53-responsive elements (p53-
RE) in mouse FATS promoter. The p53-binding site is composed of a half-site RRRCWWGYYY followed by a spacer, usually composed of 0-13 base pairs,
which is then followed by a second half-site RRRCWWGYYY sequence [3,4]. R, purine; Y, pyrimidine; W, adenine or thymine. The responsive elements of
the testis-determining factor SRY (SRY-REs) in mouse FATS promoter were analyzed by TFsearch program http://www.cbrc.jp/research/db/TFSEARCH.
html. (D) The expression level of FATS mRNA in mouse testis and ovary was determined by RT-PCR. (E) FATS protein levels in mouse tissues. Exp.:
exposure.
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Page 2 of 7transcript in GenBank (NM_001081331), whose exon 1
was not present in the cDNA clone identified or unde-
tectable by RT-PCR in our study (Figure 1B and data
not shown). Identification of FATS transcript variant
GQ499374 revealed a new promoter region of FATS
gene.
Given that p53 insufficiency, which also impairs DNA
repair, markedly increases the risk of FATS deletion and
insufficiency [3,5,6], we evaluated whether FATS might
be a transcription target of p53. Bioinformatics analysis
indicated the presence of two p53-REs within 1.3 kb
upstream of transcriptional start site (TSS) of mouse
FATS (GQ499374), but not within 2.0 kb upstream of
TSS of transcript variant NM_001081331 (Figure 1C
and data not shown). Interestingly, FATS promoter also
contains multiple AACAAT consensus motifs (Figure
1C), which are binding sites of a family of testis-deter-
mining factor SRY [7,8]. Consistently, the expression
level of FATS mRNA was much higher in mouse testis
in comparison to that in ovary, brain and lung (Figure
1D). To validate the high expression of FATS in testis,
lysates from these tissues were subjected to immuno-
blotting using an antibody specific to FATS. Indeed, the
expression level of FATS protein was the highest in tes-
tis (Figure 1E). Moreover, the expression levels of FATS
protein in ovary, lung and brain were not proportional
to their mRNA levels (Figure 1D and 1E), suggesting the
involvement of tissue-specific and posttranscriptional
regulation of FATS expression.
There is only one p53-RE (at -703 to -683 bp) within
the promoter region of human FATS, whose promoter
also contains multiple SRY-REs (Figure 2A). To deter-
mine whether this p53-RE might be functional, we
cloned human FATS promoter and generated a lucifer-
ase reporter 746-luc (Figure 2B). The reporter 746-luc
was transfected alone or co-transfected with a p53-
expressing vector into U87 cells (p53 wild-type) derived
from human glioblastoma. The luciferase activity driven
by FATS promoter was significantly higher in the pre-
sence of p53 (Figure 2C), indicating that p53 can regu-
late FATS gene. To investigate whether p53 directly
regulates the transcription of FATS, chromatin immu-
noprecipitation (ChIP) was performed to detect the phy-
sical binding of p53 to FATS promoter in vivo.
Chromatins from human U87 cells or primary mouse
embryonic fibroblast (MEF) cells were incubated with
p53 antibody or IgG control, respectively. Purified DNA
was then analyzed by PCR using primers specific for
FATS promoter. PCR product was observed after immu-
noprecipitation with anti-p53 only from precipitated
DNA containing p53-RE but not in the IgG ChIP or the
“no DNA” PCR control (Figure 2D), indicating direct
regulation of FATS transcription by p53.
In consensus motif of p53-RE, the most important
bases for interactions with the p53 protein are the cen-
tral CWWG nucleotides within each half-site, especially
the C and G [3,9]. To gain further insight into the regu-
latory specificity of p53-mediated transactivation of
FATS, we generated a reporter M-746-luc in which the
G at the first central CWWG of p53-RE was changed to
T through site-specific mutagenesis (Figure 3A). 746-luc
or M-746-luc was transfected alone or co-transfected
with p53 into U87 cells, and cell lysates were subjected
to luciferase assay subsequently [10]. The luciferase
activity driven by FATS promoter increased in the pre-
sence of p53 in a dose-dependent manner. However, the
basal luciferase level after M-746-luc transfection alone
in U87 cells was lower than that after 746-luc transfec-
tion, and site-directed mutagenesis in p53-RE abolished
p53-mediated enhancement of luciferase activity derived
from M-746-luc under the same conditions (Figure 3B).
Consistently, the luciferase activity derived from 746-luc
was not significantly higher than that from M-746-luc in
p53-null cells. However, the luciferase activity driven
by mutant, but not wild-type, FATS promoter, failed
to increase after p53 transfection into p53-null cells
(Figure 3C). These results demonstrated that p53 speci-
fically regulated the transcription of FATS.
To provide a physiological context for our findings, we
next examined whether the transcription of FATS might
be stimulated after exposure to DNA-damaging agents,
resulting from the activation of p53 [11]. MEF cells were
either untreated or treated with etoposide, an inhibitor of
DNA topoisomerase II. After 4 h, total RNA was pre-
pared and subjected to reverse transcrtiption and poly-
merase chain reaction (RT-PCR) subsequently. Indeed,
the mRNA level of FATS was significantly increased after
etoposide treatment (Figure 3D), further supporting that
FATS is a transcription target of p53 involved in DNA
damage response. The induction of p53 protein after
treatment of etoposide not only led to p21 induction but
also accompanied the induction of FATS protein (Figure
3E). Furthermore, the FATS mRNA level increased after
the treatment of other DNA damage agents such as
ionizing radiation, UV and actinomycin D (Figure 3F).
The induction of FATS after exposure to DNA-damaging
agents was significantly compromised in p53-null cells
(Figure 3G). Taken together, these results demonstrated
that FATS was induced in the DNA damage response in
a p53-dependent manner.
We further evaluated the association of FATS with
human cancers. The expression levels of FATS mRNA
in nine cancer cell lines, including MDA-MB-231,
SKBR3, MCF-7, MDA-MB-468 (breast cancer), U2OS
(osteosarcoma), H1299 (lung cancer), SKOV3/ip-1
(ovarian cancer), HeLa (cervical cancer) and HCT116
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Page 3 of 7(colon cancer) were detected by RT-PCR. FATS mRNA
was undetectable in 7 out of 9 tested cell lines, and
trace amount of FATS mRNA was expressed in
HCT116 cells (Figure 4A). Two exons of FATS on chro-
mosome 10 and one exon of GAPDH on chromosome
12 were simulteneously amplified by PCR using the
same amount of genomic DNA. Homologous deletion of
FATS gene in these cancer cells did not occur. However,
the quantity of amplified FATS DNA fragment was sig-
nificantly less in comparison with that of GAPDH DNA
control in all these cancer cells (Figure 4A), indicating
that the loss of mRNA expression of FATS is not only
due to genomic deletion of coding strand in cancer gen-
ome, which is supported by loss of heterozygosity
(LOH) studies [12,13], but also due to inhibition of gene
transcription. Consistently, the expression of FATS pro-
tein was negative in 80% (n = 15) ovarian tumors, which
was examined by immunohistochemistry, RT-PCR and
immunoblotting (Figure 4B). These results, in agreement
with frequent deletion of FATS locus in mouse tumors
[5], further suggest the role of FATS as a tumor sup-
pressor. To validate the function of FATS in suppression
of tumorigenesis, we established a FATS-expressing
stable cell line (HeLa-FATS) and its control (HeLa-
pcDNA3) to examine the anti-tumor activities of FATS.
The overexpression of FATS not only suppressed the
growth of HeLa cancer cells in vitro (Figure 4C), but
also suppressed the tumor growth in xenograft tumor
models (Figure 4D). Because p53 is inactivated in HeLa
cells, these results demonstrate that FATS is capable of
suppressing tumor growth in the absence of functional
p53.
The main outcomes after the activation of p53 include
apoptosis, senescence or cell-cycle arrest. The first two
Figure 2 FATS is a transcriptional target of p53. (A) The p53-RE sequence in the promoter of human FATS gene (GenBank accession number:
NM_001004298). The sequences of SRY-REs were also shown. (B) The sequence (-746 to +33) around TSS of human FATS was amplified by PCR and a
luciferase reporter 746-luc was constructed subsequently. The sequence of a p53-RE was highlighted, and the primer sequences were underlined. (C)
746-luc (0.5 μg) was transfected with or without p53 (0.1 μg) by Lipofactamine (Invitrogen) into U87 cells carrying wild-type p53. A reporter pRL-TK (0.1
μg, Promega) was used as internal control for trasnfection. After 24 h, dual luciferase assay was performed [10], and the firefly lucifease activity derived
from 746-luc was normalized by Renilla luciferase activity derived from pRL-TK. Results of three independent experiments were averaged and plotted
as relative luciferase activity. Error bars refer to standard deviation (± SD). (D) U87 or MEF cells were treated with 1% formaldehyde for 10 min,
respectively, and subjected to chromatin immunoprecipitation (ChIP) analysis. Primer sequences were 5’-CAAGCGATTGTCCTGTCTCA-3’ and 5’-
GAGACCAGCCTGACCAACAT-3’ (human FATS); 5’-CCGCCTCAAAAGGATAAGGT-3’ and 5’-GCAGGAACAATTACAACAATATGC-3’ (mouse FATS), 5’-
GTGTCCACCTCAGGGTGTCT-3’ and 5’-CTTCAGGGCTTCGCTTATTG-3’ (no p53-RE at hFATS exon 3).
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mits DNA damage to be repaired and genome integrity
to be maintained in a stressed cell. Among hundreds of
identified p53 targeting genes [3], p21 is a well-estab-
lished transcriptional target of p53 to mediate the effect
of cell-cycle arrest. Additionally, p21 is a major determi-
nant of tumor suppression by p53, especially in case p53
loses its capacity in inducing apoptosis [14,15]. Our pre-
v i o u ss t u d yr e v e a l sF A T Sa san o v e lr e g u l a t o ro fp 2 1 ,
which promotes the protein stability of p21 to monitor
cell-cycle checkpoints after DNA damage [5]. In this
study, we showed that FATS, possessing anticancer
activities by itself, was transactivated by p53. These find-
ings indicate the crosstalk between FATS-mediated p21
stabilization and p53-mediated p21 transactivation,
which control p21 abundance tighter (Figure 4E).
It’s interesting that FATS is a tumor suppressor highly
expressed in testis, which is likely to be mediated by a
transcriptional activator SRY (sex-determining region
Y). SRY is a sex-determining gene on the mammalian Y
chromosome and the founder member of the Sox
(Sry-related HMG box) gene family [7,8,16]. Given that
Figure 3 Effect of site-specific mutagenesis and DNA damage on p53-mediated transactivation of FATS. (A) Site-directed mutagenesis in
p53-RE consensus to generate M-746-luc. (B) The reporters was tranfected alone, or co-transfected with increased amount of p53 (0.1 μg, 0.3 μg,
respectively) into U87 cells. Dual luciferase activities were measured after 24 h. (C) Luciferase reporter assay in p53-null cells. (D) MEF cells were
untreated or treated with etoposide (0.1 μg/ml) for 4 h. The total RNA was prepared and the expression of FATS mRNA was subsequently
detected by RT-PCR. A negative control (Ctr.) with no reverse transcriptase was also showed. (E) MEF cells were untreated or treated with
etoposide (0.1 μg/ml) for 6 h. Cell lysates were prepared and subjected to immunoblotting. (F) U87 cells were untreated or treated with ionizing
radiation (IR, 10Gy), UV (4 kJ/m
2), or actinomycin D (Act.D, 20 nM), respectively. The expression of FATS mRNA was detected by RT-PCR. (G)
Induction of FATS protein in p53-null MEF cells with or without etoposide (0.1 μg/ml) treatment for 4 h.
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Page 5 of 7testis is an important organ for spermatogenesis and
that a programmed DNA fragmentation and DNA
damage response occur during the chromatin remodel-
ing steps in spermatids [17,18], the high expression of
FATS under transcriptional activation by p53 in sperma-
tids may be critical to maintain genomic stability during
spermiogenesis, which is extremely vulnerable to DNA
damage. Our findings indicate that FATS is a novel tar-
get of p53 to achieve tighter control of p21 and stronger
effect of cell-cycle arrest in surveillance of genomic
stability.
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Figure 4 The expression of FATS in human cancers and FATS-mediated tumor-suppressing activity.( A )T h em R N Al e v e l so fF A T Si n
human cancer cell lines. The primers for FATS expression: 5’-CAATAAGCGAAGCCCTGAAG-3’ and 5’-TTGGAGAGCTATCCCCAATG -3’. The same
amount of genomic DNA (0.05 μg) was used for PCR amplification (25 cycles) simulteneously. Primer sequences were as follows: 5’-
GTGTCCACCTCAGGGTGTCT-3’ and 5’-CTTCAGGGCTTCGCTTATTG-3’ (FATS exon 3); 5’-CCCATCAGAGAGGCCTGATA-3’ (FATS exon 9); 5’-
ACCCAGAAGACTGTGGATGG-3’ and 5’-TTCTAGACGGCAGGTCAGGT-3’ (GAPDH exon 8). Chr., Chromosome. (B) Immunohistochemistry of FATS in
ovarian cancer samples. Representative slide photography showing intense staining of normal ovarian section whereas negative staining in 80%
(n = 15) tested ovarian cancer samples. The percentage of positive staining of FATS was showed in right panel. Normal, N; Tumor, T. The
expression of FATS in normal ovarian tissues and ovarian tumor samples were also examined by RT-PCR and immunoblotting. The representative
images were shown in the right panel. (C) The effect of FATS on the growth of HeLa cancer cells in vitro. HeLa cells were stably transfected with
FATS and an empty vector pcDNA3 (Invitrogen), respectively. The growth rates of HeLa-FATS and HeLa-pcDNA3 cells were measured by MTT
assay [5]. The expression of FATS in HeLa-FATS cells was shown in the right panel. (D) In vivo tumorigenicity analysis of HeLa-FATS and HeLa-
pcDNA3 cells. Xenograft tumor volumes in SCID mice were measured (n = 10 mice per group) using the formula: Volume = S × S × L/2, where
S is the short length of the tumor in mm and L is the long length of the tumor in mm. (E) Schematic representation showing that p53-
mediated transactivation of FATS maximizes the effect on maintaining p21 abundance, leading to the suppression of tumorigenesis.
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